TY - JOUR
T1 - Relapse of Creosote poisoning
T2 - report of a case taking Seirogan tablets
AU - Kajimoto, Shintaro
AU - Tanaka, Takaya
AU - Hirakawa, Akihiko
AU - Shinya, Hiroshi
AU - Matsuo, Nobuaki
AU - Nakatani, Toshio
PY - 2002/7
Y1 - 2002/7
N2 - A thirty-eight year old man took about 180 tablets of Seirogan. He was unconscious and had dyspnea with dark brown urine on admission. He recovered gradually after initial treatment. Seirogan contains a phenolic component. Symptoms and signs of poisoning are unconsciousness, convulsion, digestive tract disorder, pulmonary edema, hepatic failure, renal failure, and miosis. Clinical features include dark brown urine. On day 7, he again showed signs of creosote poisoning: relapse of unconsciousness and dark colored urine. Plasma concentration of phenol determined on the day before the relapse was much higher than that expected from the half-life of blood phenol. It is reported that Creosote poisoning results in a decrease in the intestinal peristalsis, or paralytic ileus. We would like to emphasize that a relapse of Creosote poisoning may occur due to possible delayed absorption of the Seirogan tablets.
AB - A thirty-eight year old man took about 180 tablets of Seirogan. He was unconscious and had dyspnea with dark brown urine on admission. He recovered gradually after initial treatment. Seirogan contains a phenolic component. Symptoms and signs of poisoning are unconsciousness, convulsion, digestive tract disorder, pulmonary edema, hepatic failure, renal failure, and miosis. Clinical features include dark brown urine. On day 7, he again showed signs of creosote poisoning: relapse of unconsciousness and dark colored urine. Plasma concentration of phenol determined on the day before the relapse was much higher than that expected from the half-life of blood phenol. It is reported that Creosote poisoning results in a decrease in the intestinal peristalsis, or paralytic ileus. We would like to emphasize that a relapse of Creosote poisoning may occur due to possible delayed absorption of the Seirogan tablets.
UR - http://www.scopus.com/inward/record.url?scp=0036636810&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036636810&partnerID=8YFLogxK
M3 - Article
C2 - 12415872
AN - SCOPUS:0036636810
SN - 0914-3777
VL - 15
SP - 293
EP - 296
JO - Chūdoku kenkyū : Chūdoku Kenkyūkai jun kikanshi = The Japanese journal of toxicology
JF - Chūdoku kenkyū : Chūdoku Kenkyūkai jun kikanshi = The Japanese journal of toxicology
IS - 3
ER -